Evidence-based progress for the risk events of paclitaxel devices in treatment of peripheral artery disease
10.3760/cma.j.cn112139-20200928-00733
- VernacularTitle:下肢动脉疾病应用紫杉醇载药器械后风险事件的循证进展
- Author:
Jianfeng SUN
1
;
Fei MEI
;
Kewei WANG
;
Wenfei GUAN
;
Heyue JIA
;
Jiang XIONG
Author Information
1. 三峡大学第一临床医学院 宜昌市中心人民医院血管外科，湖北宜昌 443003
- Keywords:
Arteriosclerosis obliterans;
Lower extremity;
Paclitaxel-coated balloon;
Paclitaxel-eluting stent;
Mortality
- From:
Chinese Journal of Surgery
2021;59(8):716-720
- CountryChina
- Language:Chinese
-
Abstract:
With the development of endovascular technology for peripheral arterial diseases, paclitaxel drug-eluting stents and drug-coated balloons have been widely used in recent years. It has been proved that paclitaxel-coated devices have good clinical effects in reducing vascular restenosis. However, the clinical safety of paclitaxel devices has encountered challenges, some of the studies have shown that paclitaxel-coated devices may increase long-term mortality. In addition, some studies have confirmed the effectiveness and safety of paclitaxel devices, leading to this topic becoming the focus and hot spot of global attention. Whether paclitaxel-coated devices increase the risk of long-term death, whether paclitaxel doses are related to mortality, and the pharmacokinetics of paclitaxel devices should be examined.
